# Analysis of Adolescent HIV Care Cascade Outcomes in PEPFAR-Supported Programs in Central America, October 2020–September 2024

**Authors:** Lissette Raquel Chang, Cristine Gutierrez, Jose Rodas, Nancy Aitcheson, Nasim Farach, Carlos Castaneda, Andres Azmitia Rugg, Benjamin Ryan Phelps

PMC · DOI: 10.3390/tropicalmed11010005 · Tropical Medicine and Infectious Disease · 2025-12-24

## TL;DR

This study examines HIV care outcomes for adolescents in Central America, showing progress in treatment but highlighting ongoing challenges in early diagnosis and viral load monitoring.

## Contribution

The paper provides updated empirical data on adolescent HIV care cascade outcomes in PEPFAR-supported Central American countries from 2020 to 2024.

## Key findings

- Adolescent HIV testing increased, but positivity rates remained stable at around 2%.
- Viral load suppression improved regionally from 73% to 90%, though viral load coverage remains a challenge at 80%.
- Advanced HIV disease at diagnosis is high (34%), especially among females (40%).

## Abstract

To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** AIDS (MESH:D000163), AHD (MESH:D015658)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12846695/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12846695/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12846695/full.md

---
Source: https://tomesphere.com/paper/PMC12846695